暂无数据
代码股票名称
最新价涨跌额涨跌幅成交量成交额今开昨收最高最低总市值流通市值总股本流通股本5日涨跌幅10日涨跌幅20日涨跌幅60日涨跌幅120日涨跌幅250日涨跌幅年初至今涨跌幅股息率TTM换手率市盈率TTM市盈率(静)振幅所属行业
美股期权个股详情
NNVC240517C7500
- 0.00
- 0.000.00%
延时15分钟行情交易中 05/23 09:30 (美东)
0.00最高价0.00最低价
0.00今开0.00昨收0张成交量0张未平仓合约数7.50行权价0.00成交额0.00%隐含波动率237.26%溢价2024/05/17到期日0.00内在价值100合约乘数-5天距到期日0.00时间价值100合约规模美式期权类型--Delta--Gamma--杠杆倍数--Theta--Rho--有效杠杆--Vega
分时
- 5日
- 日K
暂无内容
新闻
NanoViricides 加强合作努力-Engages Aagami Inc.
与主动医疗分析师约翰·萨文博士一起分析纳米病毒向呼吸道合胞病毒治疗的转变 | NYSE-A: NNVC
经口服 NV-387 治疗的致命呼吸道合胞病毒感染动物肺组织学表现正常，表明有可能治愈
NV-387，一种广谱抗病毒药物，对呼吸道合胞病毒、甲型流感、冠状病毒等具有很强的活性，康涅狄格州谢尔顿/ACCESSWIRE/2024年5月20日/NanoViricides, Inc.（纽约证券交易所美国股票代码：nnVC）（“公司
nanoviricides 报告 NV-387 对呼吸道合胞病毒具有很强的抗病毒活性 | NYSE-A: NNVC
周四盘中交易时段，12只医疗保健类股走势
在周四的例会中，GainerSlucy Scientific Discovery（纳斯达克股票代码：LSDI）股价上涨了205.8％，至1.56美元。该公司的市值为270万美元。SINTX Techs（纳斯达克股票代码：SINT）sha
NanoViricides | 10-Q：季度报表
评论
$NanoViricides(NNVC.US$
NEWS
NanoViricides Bolsters Partnership Efforts - Engages Aagami Inc
NanoViricides has engaged Aagami Inc. to seek licensing and partnering opportunities for its key asset, NV-387, and platform technology in India and Japan. NV-387, a broad-spectrum antiviral nanomedicine, has completed Phase I clinical trials in healthy subjects with no adverse effects reported. It is now ready for Phase II trials.
NV-387, designed to mimic host-side virus-binding features, targets a wi...
NEWS
NanoViricides Bolsters Partnership Efforts - Engages Aagami Inc
NanoViricides has engaged Aagami Inc. to seek licensing and partnering opportunities for its key asset, NV-387, and platform technology in India and Japan. NV-387, a broad-spectrum antiviral nanomedicine, has completed Phase I clinical trials in healthy subjects with no adverse effects reported. It is now ready for Phase II trials.
NV-387, designed to mimic host-side virus-binding features, targets a wi...
1
2
$NanoViricides(NNVC.US$
NEWS
A Novel Broad-Spectrum Antiviral with Activity Against RSV
NanoViricides announced that its antiviral drug candidate, NV-387, showed complete survival in mice lethally infected with RSV (Respiratory Syncytial Virus) in a recent study.
The study compared NV-387 with the currently approved RSV treatment, ribavirin. While NV-387 led to the complete survival of animals over a 21-day period, ribavirin resulted in the death of all subjects by day 14.
RSV is a major cause ...
NEWS
A Novel Broad-Spectrum Antiviral with Activity Against RSV
NanoViricides announced that its antiviral drug candidate, NV-387, showed complete survival in mice lethally infected with RSV (Respiratory Syncytial Virus) in a recent study.
The study compared NV-387 with the currently approved RSV treatment, ribavirin. While NV-387 led to the complete survival of animals over a 21-day period, ribavirin resulted in the death of all subjects by day 14.
RSV is a major cause ...
1
1
$Scynexis(SCYX.US$
$NanoViricides(NNVC.US$
$泰尼特(THC.US$
I want to watch these the most, I think, and now to find stuff in a different sector..
$NanoViricides(NNVC.US$
$泰尼特(THC.US$
I want to watch these the most, I think, and now to find stuff in a different sector..
1
$NanoViricides(NNVC.US$
NEWS
A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox
NanoViricides, Inc. announces NV-387, a novel broad-spectrum antiviral with activity against Smallpox/Mpox. NV-387 shows strong orthopoxvirus activity against Smallpox/Mpox, both inhalation and skin abrasion modes. Animal studies demonstrate increased survival compared to tecovirimat, approved for Smallpox. NV-387 potentially reduces tecovirimat resistance. NanoViricides focuses on developing antiv...
NEWS
A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox
NanoViricides, Inc. announces NV-387, a novel broad-spectrum antiviral with activity against Smallpox/Mpox. NV-387 shows strong orthopoxvirus activity against Smallpox/Mpox, both inhalation and skin abrasion modes. Animal studies demonstrate increased survival compared to tecovirimat, approved for Smallpox. NV-387 potentially reduces tecovirimat resistance. NanoViricides focuses on developing antiv...
1
阅读更多